Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019240 · ClinicalTrials.gov registry record · Phase 2
Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV Infection
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00019240: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00019240 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019240, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Herpesvirus is found in Kaposi's sarcoma lesions in most patients; it is therefore possible that the herpesvirus has a role in causing Kaposi's sarcoma. Cidofovir is an antiviral drug that acts against many types of herpesvirus, and may be an effective treatment for Kaposi's sarcoma. PURPOSE: Phase II trial to study the effectiveness of cidofovir in treating patients with Kaposi's sarcoma with or without HIV infection.
Interventions
- DRUG cidofovir
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-11 |
| Est. Completion | 2004-04 |
| Phase | Phase 2 |
What the finished NCT00019240 record still lists
NCT00019240 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which cidofovir is the first listed.
NCT00019240 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00019240 about?
NCT00019240 is a clinical study titled "Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV Infection". RATIONALE: Herpesvirus is found in Kaposi's sarcoma lesions in most patients; it is therefore possible that the herpesvirus has a role in causing Kaposi's sarcoma. Cidofovir is an antiviral drug that acts against many types of herpesvirus, and may be an effective treatment for Kaposi's sarcoma. PUR...
What is the current status of trial NCT00019240?
This trial is currently completed. It is a Phase 2 study. The study started on 1996-11. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00019240?
The interventions under investigation include: cidofovir (DRUG).
Who is sponsoring clinical trial NCT00019240?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia